...
首页> 外文期刊>The American journal of hospice and palliative care >Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.
【24h】

Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.

机译:美洛昔康和选择性COX-2抑制剂可缓解姑息治疗人群的疼痛。

获取原文
获取原文并翻译 | 示例
           

摘要

This paper discusses the treatment of pain in the palliative care patient, specifically the use of meloxicam and recent advances in agents with cyclooxygenase-2 (COX-2) selectivity. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that preferentially inhibits COX-2 more than cyclooxygenase-1 (COX-1), especially at low doses, thereby offering advantages over traditional nonselective NSAIDs. New COX-2 selective agents are discussed, including valdecoxib, parecoxib, etoricoxib, and COX-189.
机译:本文讨论了姑息治疗患者的疼痛治疗,特别是美洛昔康的使用以及具有环氧合酶2(COX-2)选择性的药物的最新进展。美洛昔康是一种非甾体类抗炎药(NSAID),与环加氧酶-1(COX-1)相比,其抑制COX-2的优先级更高,尤其是在低剂量时,因此具有优于传统非选择性NSAID的优势。讨论了新的COX-2选择性药物,包括伐地考昔,帕瑞昔布,依托昔布和COX-189。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号